TTP 4000

Drug Profile

TTP 4000

Alternative Names: TTP4000

Latest Information Update: 12 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator TransTech Pharma
  • Developer vTv Therapeutics LLC
  • Class
  • Mechanism of Action Advanced glycosylation end product inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 01 Oct 2011 Phase-I clinical trials in Alzheimer's disease (In adults, In the elderly) in USA (SC) (NCT01548430)
  • 12 Aug 2009 Preclinical development is ongoing in USA
  • 21 Sep 2006 TransTech Pharma and Pfizer have entered into an license agreement for the development and commercialisation of RAGE modulators worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top